Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 263-268

  Goto, Tomoko ^a   Takano, Masashi ^a   Watanabe, Akio ^a   Miyamoto, Morikazu ^a   Kato, Masafumi ^a   Hirata, Junko ^a   Sasa, Hidenori ^a   Furuya, Kenichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

CA125; Ovarian cancer; Prognosis; Recurrence; Secondary cytoreductive surgery

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; EPITHELIUM TUMOR; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; REMISSION; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; UTERINE TUBE CARCINOMA;

AGED; CA-125 ANTIGEN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79956101460     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182098002     Document Type: Article

References (29)

1. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88: 144-153. (Pubitemid 30027690)
2. Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992;70:2129-2136.
3. Segna RA, Dottino PR, Mandeli JP, et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. Clin Oncol. 1993;11:434-439. (Pubitemid 23071038)
4. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol. 2000;79:344-349.
5. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504-512. (Pubitemid 33139711)
6. Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002;99:1008-1013. (Pubitemid 34621223)
7. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161. (Pubitemid 38325942)
8. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92:1026-1032. (Pubitemid 40546664)
9. Ayhan A, Gultekin M, Taskiran C, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Ostet Gynecol. 2006;194:49-56. (Pubitemid 43017774)
10. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-1939. (Pubitemid 43673208)
11. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14:1136-1142.
12. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685-691. (Pubitemid 46233229)
13. Bae J, Lim MC, Choi JH, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;20:101-106.
14. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324-1330.
15. Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2010;101: 418-424.
16. Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101:244-250.
17. Biliatis I, Haidopoulos D, Rodolakis A, et al. Survival after secondary cytoreduction for recurrent ovarian cancer: which are the prognostic factors? J Surg Oncol. 2010;102: 671-675.
18. Sehouli J, Richter R, Braicu EI, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656-662.
19. Woelber L, Jung S, Eulenburg C, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol. 2010;36: 583-588.
20. Treatment Guidelines for Ovarian Cancer 2007 Edition. Japan Society of Gynecologic Oncology.
21. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534-1535.
22. Mahner S, Woelber L, Jung S, et al. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. Anticancer Res. 2009;29:2817-2821.
23. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117: 336-340.
24. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomized trial. Lancet. 2010;376:1155-1163.
25. Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010;7:335-339.
26. Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol. 2010;22: 498-502.
27. Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;6:CD007822
28. Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010;20: 936-944.
29. Pan HS, Lee SL, Huang LW, et al. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet. 2010 [Epub ahead of print].